Sage Therapeutics, Inc.
SAGE
$6.75
$0.192.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 29.56% | 26.01% | 48.53% | 24.67% | 9.76% |
| Total Depreciation and Amortization | -42.60% | -25.99% | 2.90% | 13.42% | 20.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -33.48% | -28.73% | -5.34% | 34.19% | 0.48% |
| Change in Net Operating Assets | -92.35% | 225.79% | -194.07% | -91.83% | 229.76% |
| Cash from Operations | 26.76% | 50.57% | 41.58% | 29.63% | 16.05% |
| Capital Expenditure | -- | -- | 111.83% | 78.03% | 66.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -55.38% | -39.87% | -46.69% | -22.72% | -26.95% |
| Cash from Investing | -55.35% | -39.79% | -46.57% | -22.59% | -26.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 90.19% | 61.39% | 60.62% | 130.48% | 12.42% |
| Repurchase of Common Stock | -79.71% | 55.26% | -2.95% | 58.99% | 58.93% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 88.40% | 76.92% | 64.66% | 154.05% | 24.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -298.29% | 111.07% | 6.79% | 76.46% | -215.99% |